-

09:11:04 PM

MRNA Stock News

MRNA - Moderna Inc

06/22/22 7:03 AM

Nasdaq : MRNA

Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company

RHEA-AI

neutral

06/21/22 7:05 PM

Nasdaq : MRNA

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom

Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses Moderna would expand its presence in the UK through investments in R&D activities and capabilities Collaboration would support the UK with direct access to rapid pandemic response

RHEA-AI

neutral

06/17/22 9:05 AM

Nasdaq : MRNA

covid-19

Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older

mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart mRNA-1273 has been administered to millions of children and adolescents over the age of 6 worldwide, with safety and tolerability profiles consistent with

RHEA-AI

positive

06/08/22 7:00 AM

Nasdaq : MRNA

Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron

Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant mRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean Titers Against Omicron Among Baseline Seronegative Participants Safety and Tolerability Profile

RHEA-AI

negative

06/07/22 7:00 AM

Nasdaq : MRNA

clinical trial

Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)

mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trial mRNA-1010 is one of several influenza vaccine candidates being developed in Moderna's respiratory portfolio Moderna now has four programs in Phase 3 studies: Omicron-containing bivalent COVID booster,

RHEA-AI

neutral

06/02/22 6:30 AM

Nasdaq : MRNA

covid-19

Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the Moderna

RHEA-AI

neutral

06/01/22 7:57 AM

Nasdaq : MRNA

conferences

Moderna to Present at Upcoming Conferences in June 2022

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences: 2022 Jefferies Healthcare Conference on Wednesday, June 8 th

RHEA-AI

neutral

05/31/22 3:56 AM

NYSE, Nasdaq : TAK, MRNA

covid-19

Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Takeda announced to transfer...

RHEA-AI

very positive

05/31/22 3:40 AM

Nasdaq, NYSE : MRNA, TAK

covid-19

Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for Spikevax TM from August 1, 2022 Companies concluded memorandum of understanding that Takeda will continue to provide

RHEA-AI

very positive

05/18/22 3:55 PM

Nasdaq : MRNA

conferences

Moderna to Present at the UBS 2022 Global Healthcare Conference

Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24 th at 9:15 a.m. ET. A live

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next